aerothionin | 66428-69-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: aerothionin
• 英文别名: 1,4-bis-((5S)-7,9-dibromo-10t-hydroxy-8-methoxy-(5rO)-1-oxa-2-aza-spiro[4.5]deca-2,6,8-triene-3-carbonylamino)-butane；trans-trans-Aerothionin；(+)-Aerothionin；7,9-dibromo-N-[4-[(7,9-dibromo-6-hydroxy-8-methoxy-1-oxa-2-azaspiro[4.5]deca-2,7,9-triene-3-carbonyl)amino]butyl]-6-hydroxy-8-methoxy-1-oxa-2-azaspiro[4.5]deca-2,7,9-triene-3-carboxamide
• CAS: 66428-69-1；87638-40-2
• 化学式: C₂₄H₂₆Br₄N₄O₈
• 分子量: 818.108
• InChiKey: BJWQSQOWGBUSFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  40
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  160
• 氢给体数：
  4
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  aerothionin 在 manganese(IV) oxide 作用下， 以 乙酸乙酯 为溶剂， 生成 Didehydroaerothionin
  参考文献：
  名称：

  Forrester,A.R. et al., Justus Liebigs Annalen der Chemie, 1978, p. 66 - 73

  摘要：

  DOI：

文献信息

• Marine compounds with calcium channel blocking properties for Alzheimer's disease treatment
  申请人：Neuropharma S.A.U.

  公开号：EP1609783A1

  公开（公告）日：2005-12-28

  The invention provides compounds having two spiro heterocyclic units connected through a linker of a certain length. Some of these compounds have been obtained from Aplysinia sp. The compounds exhibit VDCC blocker activity as well as acetylcholinesterase and butyrylcholinesterase inhibition activities. Therefore they are useful in the treatment of use in the treatment of brain ischemia, stroke, cognitive disorders as senile dementia, cerebrovascular dementia, mild recognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimers's disease or condition, or prion disease as Creutzfeld-Jacob disease or Gerstmann-Straussler-Scheinher disease.

  本发明提供了具有两个通过一定长度的连接物连接的螺杂环单元的化合物。这些化合物具有 VDCC 阻塞活性以及乙酰胆碱酯酶和丁酰胆碱酯酶抑制活性。因此，它们可用于治疗脑缺血、中风、认知障碍（如老年性痴呆、脑血管性痴呆、轻度认知障碍、注意力缺陷障碍）和/或具有异常蛋白聚集的神经退行性痴呆疾病（如阿尔兹海默病或阿尔茨海默病），或朊病毒病（如克雅氏病或格斯特曼-斯特劳斯勒-舍海尔病）。
• MARINE COMPOUNDS WITH CALCIUM CHANNEL BLOCKING PROPERTIES FOR THE TREATMENT OF COGNITIVE OR NEURODEGENERATIVE DISEASES
  申请人：Neuropharma, S.A.

  公开号：EP1761262B1

  公开（公告）日：2008-12-03
• Transition-state Inhibitors of Pin1, alpha-Ketoamide-containing peptidomimetics, and synthesis thereof
  申请人：Etzkorn Felicia

  公开号：US20070027067A1

  公开（公告）日：2007-02-01

  Novel α-ketoamide-containing peptidomimetics are provided, such as peptidomimetics containing an α-ketoamide Ser-Pro dipeptide analogue. The α-ketoamide is preferably incorporated into another molecule as a Pin1 inhibitor (such as a pentapeptide analogue Ac-Phe-Tyr-pSer-Pro-Arg-NH 2 ).
• Marine Compounds with Calcium Channel Blocking Properties for the Treatment of Cognitive or Neurodegenerative Diseases
  申请人：Gil Ana Martinez

  公开号：US20080039513A1

  公开（公告）日：2008-02-14

  The invention provides compounds having a spiro heterocyclic unit connected through a linker of a certain length to another spiro cycle, an imidazole ring or an amide group. Some of these compounds have been obtained from Aplysinia cavernicola and a mixture of Aplysina fulva and Oceanapia . The compounds exhibit VDCC blocker activity; some also show acetylcholinesterase and butyrylcholinesterase inhibition activities. Therefore they are useful in the treatment of cognitive and neurodegenerative disorders, such as brain ischemia, stroke, cognitive disorders as senile dementia, cerebrovascular dementia, mild recognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimers's disease or condition, or prion disease as Creutzfeld-Jakob disease or Gerstmann-Straussler-Scheinker disease.
• [EN] MARINE COMPOUNDS WITH CALCIUM CHANNEL BLOCKING PROPERTIES FOR THE TREATMENT OF COGNITIVE OR NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSES MARINS POSSEDANT DES PROPRIETES BLOQUANT LES CANAUX CALCIQUES, DESTINES AU TRAITEMENT DE MALADIES COGNITIVES OU NEURODEGENERATIVES
  申请人：NEUROPHARMA SA

  公开号：WO2005123073A1

  公开（公告）日：2005-12-29

  The invention provides compounds having a spiro heterocyclic unit connected through a linker of a certain length to another spiro cycle, an imidazole ring or an amide group. Some of these compounds have been obtained from Aplysinia cavernicola and a mixture of Aplysina fulva and Oceanapia. The compounds exhibit VDCC blocker activity; some also show acetylcholinesterase and butyrylcholinesterase inhibition activities. Therefore they are useful in the treatment of cognitive and neurodegenerative disorders, such as brain ischemia, stroke, cognitive disorders as senile dementia, cerebrovascular dementia, mild recognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimers's disease or condition, or prion disease as Creutzfeld-Jakob disease or Gerstmann-Straussler-Scheinker disease.